RTP Mobile Logo
Submitted by mphilemon@resea... on Mon, 10/01/2012 - 12:33

In these audio proceedings from a closed Think Tank meeting in Miami, Florida, the invited faculty members discuss and debate current nonprotocol management of various gastrointestinal cancers in addition to relevant papers and presentations emerging over the past year in this area of solid tumor oncology. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.

Listen to audio excerpts

Track 1: Results of CORRECT: A Phase III trial of the oral multikinase inhibitor regorafenib with best supportive care vs placebo with best supportive care for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies
Track 2: Effects of prior bevacizumab on outcomes from the VELOUR study: A Phase III trial of aflibercept and FOLFIRI for patients with mCRC after failure of an oxaliplatin-based regimen
Track 3: Mechanism of action, response and toxicities of aflibercept, a potent angiogenesis inhibitor fusion protein
Track 4: Targeting angiogenesis — bevacizumab, aflibercept and regorafenib — in the treatment of mCRC
Track 5: ML18147 (TML): Results from a Phase III trial evaluating the addition of bevacizumab to crossover fluoropyrimidine-based chemotherapy for patients with mCRC experiencing disease progression on first-line chemotherapy/bevacizumab
Track 6: Plasma VEGF-A as a putative biomarker for predicting clinical outcome in patients with advanced gastric cancer (GC) treated with bevacizumab
Track 7: Perspectives on improved outcome with the use of bevacizumab beyond first disease progression in the BRiTE registry
Track 8: Case discussion: A 60-year-old patient whose Stage II colon cancer was managed without adjuvant therapy 4 years ago presents with K-ras-mutant bilateral liver and lung metastases and the disease progresses on FOLFOX/bevacizumab
Track 9: Incorporation of aflibercept into the therapeutic algorithm for mCRC
Track 10: Clinical trials evaluating ramucirumab — an IgG1 fully human monoclonal antibody targeting VEGFR-2 — in GC and hepatocellular carcinoma (HCC)
Track 11: Current status of RAISE: A Phase III study of FOLFIRI in combination with ramucirumab or placebo for patients with mCRC progressing during or after first-line therapy with bevacizumab, oxaliplatin and a fluoropyrimidine
Track 12: Clinical treatment for a patient with multiple K-ras wild-type liver metastases 4 years after diagnosis of Stage II colon cancer
Track 13: CALGB-80405: A Phase III trial of physician’s choice of FOLFOX or FOLFIRI in combination with bevacizumab or cetuximab for patients with mCRC
Track 14: Impact on survival of primary tumor resection in patients with CRC and unresectable metastasis
Track 15: NSABP-C-10: Results from a Phase II study evaluating primary mFOLFOX6 in combination with bevacizumab for patients with unresectable metastatic colon cancer and a synchronous asymptomatic primary tumor
Track 16: Association of K-ras G13D mutation with outcome in patients with mCRC treated with cetuximab
Track 17: Development of next-generation sequencing techniques to detect genomic alterations in CRC and other solid tumors
Track 18: Availability of next-generation sequencing assays to identify potential actionable targets in colon cancer and other solid tumors
Track 19: Validation of the Oncotype DX® Colon Cancer Assay Recurrence Score® as a predictor of recurrence in patients with Stage II and III colon cancer treated with 5-FU/leucovorin with or without oxaliplatin on the NSABP-C-07 trial
Track 20: Perspectives on the utility of Oncotype DX for patients with Stage II and Stage III colon cancer
Track 21: Effect of Oncotype DX Colon Cancer Assay results on treatment recommendations for patients with Stage II colon cancer
Track 22: Clinical presentation and diagnosis of carcinoid and pancreatic neuroendocrine tumors
Track 23: Sequencing of systemic therapeutic options for patients with pancreatic neuroendocrine tumors
Track 24: Role of the somatostatin analog octreotide in the treatment of neuroendocrine tumors
Track 25: Therapeutic options for unresectable pancreatic neuroendocrine tumors
Track 26: Octreotide for the treatment of carcinoid neuroendocrine tumors
Track 27: Efficacy, multivariate and biomarker analyses from RADIANT-2: A Phase III trial of octreotide in combination with everolimus or placebo for patients with advanced neuroendocrine tumors
Track 28: Emerging roles of everolimus and sunitinib in the treatment of neuroendocrine tumors
Track 29: Early study results and ongoing clinical trials of bevacizumab-based therapies for patients with pancreatic neuroendocrine tumors
Track 30: Results of the SSG XVIII study: 12 versus 36 months of adjuvant imatinib for operable, high-risk gastrointestinal stromal tumors (GIST)
Track 31: Case discussion: A 44-year-old man with a jejunul mass undergoes resection for a 6-cm GIST with a mitotic index of 7 per HPF and has been receiving imatinib for 25 months
Track 32: Case discussion: A 67-year-old man with gastric GIST refuses adjuvant imatinib after resection, develops nodal and liver metastases 3 years later and attains a partial response to imatinib but desires to stop therapy after 3 years
Track 33: Use of nomograms to develop a threshold risk of recurrence at which to administer adjuvant imatinib therapy for GIST
Track 34: Current role of mutational testing and mechanisms of resistance to imatinib therapy in GIST
Track 35: Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GIST after failure of imatinib and sunitinib
Track 36: Ongoing trial strategies in GIST: Evaluation of the second-generation tyrosine kinase inhibitor nilotinib versus imatinib re-treatment after disease progression
Track 37: Perspectives on the potential role of regorafenib in GIST
Track 38: Transarterial chemoembolization (TACE) with or without sorafenib in HCC
Track 39: GIDEON registry: A global investigation of therapeutic decisions by oncologists and hepatologists/gastroenterologists on the use of sorafenib in the management of HCC
Track 40: Use of sorafenib in advanced Child-Pugh B HCC and management of treatment-related hand-foot syndrome
Track 41: Clinical criteria for liver transplant in HCC
Track 42: Appropriate use of TACE and multidisciplinary management of HCC
Track 43: Potential role for mTOR inhibitors in the treatment of HCC
Track 44: Challenges in the development of therapeutic agents for HCC

Additional audio available exclusively online
Track 1: Case discussion: A 69-year-old man status-post Whipple procedure for a 3.5-cm adenocarcinoma of the pancreas with 2 positive lymph nodes and negative margins
Track 2: Potential use of neoadjuvant FOLFIRINOX for patients with borderline resectable or unresectable pancreatic cancer (PC)
Track 3: Next-generation sequencing and detection of actionable targets in PC by immunohistochemistry, microarray fluorescence in situ hybridization and mutational analysis
Track 4: Classification, differential management and outcomes of biliary tract cancers
Track 5: Case discussion: A 75-year-old man with a history of abdominal distress, burping and suspected gallbladder disease is diagnosed with unresectable extrahepatic bile duct cancer and receives cisplatin/gemcitabine
Track 6: Frequent mutation of isocitrate dehydrogenase (IDH)-1 and IDH-2 in cholangiocarcinoma identified through broad-based tumor genotyping
Track 7: Adjuvant therapy in the treatment of biliary tract cancer
Track 8: Practical considerations and challenges — disease subclassifications and inadequate preclinical/animal modeling — in the diagnosis and treatment of pancreatic and biliary tract cancers
Track 9: Perspectives on current therapeutic agents and regimens — gemcitabine, FOLFIRINOX, FOLFIRI and nanoparticle albumin-bound (nab) paclitaxel — in PC
Track 10: Critical evaluation of clinical trial designs
Track 11: Clinical management of HER2-positive GC
Track 12: Therapeutic options for HER2-negative advanced GC
Track 13: Role of neoadjuvant chemotherapy in GC and potential considerations for the addition of trastuzumab for patients with HER2-positive GC
Track 14: Preoperative chemoradiation therapy for esophageal or gastroesophageal junction cancer
Track 15: Case discussion: A 39-year-old man with confirmed HIV infection presents with a 4-cm squamous cell anal carcinoma
 
FACULTY:
 
Tanios Bekaii-Saab, MD
Section Chief
Gastrointestinal Oncology
Chair, CCC Gastrointestinal Disease
Research Group
Associate Professor of Medicine
and Pharmacology
The Ohio State University
James Cancer Hospital
Columbus, Ohio
 
Emily K Bergsland, MD
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California
 
Charles S Fuchs, MD, MPH
Director
Center for Gastrointestinal Cancer
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Richard M Goldberg, MD
Professor of Medicine
Physician-in-Chief, OSUCCC
James Cancer Hospital and
Richard J Solove
Research Institute
Klotz Family Chair in Cancer Research
The Ohio State University
Columbus, Ohio
 
Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota
 
Matthew Kulke, MD, MMSc
Director, Program in Neuroendocrine
and Carcinoid Tumors
Dana-Farber/Brigham and
Women’s Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Bert H O’Neil, MD
Associate Professor
Director, GI Oncology Clinical
Research Program
Medical Director, UNC Cancer Clinical
Trials Protocol Office
UNC Lineberger Comprehensive
Cancer Center
Chapel Hill, North Carolina
 
Alan P Venook, MD
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida